Prosecution Insights
Last updated: November 04, 2026
Application No. 19/132,226

TOLEROGENIC COMPOSITION

Non-Final OA §103§112
Filed
May 22, 2025
Priority
Nov 23, 2022 — EU 22383126.4 +1 more
Examiner
STEVENS, MARK V
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Universitat De Lleida
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
1y 2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
575 granted / 879 resolved
+5.4% vs TC avg
Strong +42% interview lift
Without
With
+41.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
45 currently pending
Career history
949
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
39.8%
-0.2% vs TC avg
§102
11.7%
-28.3% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 879 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 12-15 are cancelled. Claims 17-20 are new. Claims 1-11 and 16- 20 are pending and under examination. Priority This application is a national stage entry of PCT/EP2023/082656 filed on 11/22/2023, which claims priority from EP22383126.4 filed on 11/23/2022. Information Disclosure Statement The information disclosure statements filed on 05/22/2025 and 07/16/2025 have been considered by the examiner. Claim Objections Claims 9 and 20 use “selected from… and…” but are not written in Markush form of “selected from the group consisting of”. The applicant may change the “and” to “or” for these options. Claim 8 is objected to for “chromogranin and islet-glucose-6-phosphatase….”, which should be “chromogranin, islet-glucose-6-phosphatase…” Appropriate correction is required. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 8 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 8 uses recitation of “derivatives” that may apply to items found above. Applicant does not provide for a definition of derivatives that would limit it to particular defined derivations nor provide a representative number of derivative species that would provide ownership for such a genus. It appears the only derivation discussed with detail is “antigenic fragments” or “immunogenic fragments”, but derivations would encompass a larger number of added chemical groups or alterations that would alter the function of the items (e.g. peptides or proteins) in a variety of ways and with a variety of functionalities not described. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7-9, 16, and 18-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 7 and 18 are indefinite for the use of “including” in the claim in the recitations “drugs, including therapeutic proteins” and “viral vectors, including viral capsid proteins” as it is unclear if “drugs” is supposed to necessarily include therapeutic proteins and if “viral vectors” is supposed to necessarily include viral capsid proteins or if “including” as provided in these claims is being used for examples of what “drugs” or “viral vectors” may be. Applicant may simply use “therapeutic proteins” and “viral capsid proteins” to simplify and clarify these recitations. It is also unclear how all drugs or viral vectors would necessarily serve as antigens, which seems to be the purpose of this group of items. Claims 8, 9, 19 and 20 are rejected as being dependent on an indefinite claim. Claim 16 recites the limitation "the liposomes" in the claim where claim 1, on which it depends, provides for liposomes in the first population and liposomes in the second population. It is unclear if “the liposomes” in claim 16 is referring to only “the liposomes in the first population”, only “the liposomes in the second population” or both “the liposomes in the first and second populations”. There is insufficient antecedent basis for this limitation in the claim. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 8 recites the broad recitation “self antigen associated with an autoimmune disease”, and the claim also recites “in particular the self-antigen is selected from…”, which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Applicant may delete the recitation of “in particular” to correct the issue. In the present instance, claim 9 recites the broad recitation “viral capsid protein”, and the claim also recites “in particular selected from VP1, VP2 and VP3”, which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Regarding claim 8, the phrase "for example" (here written as (e.g. collagen type 11) or (e.g. small nucleolar protein)) renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim 8 is indefinite for having multiple recitations of “and” within the group where the only “and” should come before the last item in the group. This makes it unclear where the Markush group should end (e.g. does it end after “and islet glucose-6-phosphatase catalytic subunit-related protein” or after “and antigenic fragments…” or after “and “immunogenic fragments….” For the purpose of compact prosecution, the examiner will read the group as containing all of the items following “consisting of”. Claim 8 is indefinite for use of “derivatives” as it is unclear what types of derivations this would encompass for the items presented in the group. However, Applicant does provide support for antigenic fragments of any of the members of the group and immunogenic fragments of any of the members of the group, which are a more specific type of derivative, but there is no definition by applicant that limits derivative to a certain item/type of derivation. For the purpose of compact prosecution. Claim 8 is indefinite for the use of “any of the above” as it is unclear if it is only referring to the items in that group or if above can related to any limitation that appears above this recitation (even those in other claims). Claim Rejections – 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 2, 4, 7, 10, 11, and 16 are rejected under 35 U.S.C. 103 as being unpatentable over CN101502649A. CN ‘649 teaches a liposome vaccine for preventing and treating influenza which encapsulates biological medicine (abstract). CN ‘469 notes that its formulation has beneficial effects including increased encapsulation of antigen (abstract). Example 4 provides for a formulation with a liposome made up of phosphatidyl serine, cholesterol and stearic acid amine in molar ratio of 7:5:3. This translates to about 66% by weight of phosphatidyl serine in the membrane. This ratio allows for Example 3 provides for use of lecithin and cholesterol for liposomes. Lecithin is primarily phosphatidylcholine (also see example 6). Claim 10 of CN ‘649 provides for materials for liposomes including phosphatidyl choline, phosphatidylserine and lecithin. Claim 9 of CN ‘649 teaches liposome diameters of 50 to 5000 nm while its disclosure also allows ranges of 100-1500 nm and 300-800 nm (English translation of CN ‘649). CN ‘649 teaches antigenic components (protein or glycoprotein) (English translation). CN ‘649 teaches additives like antioxidants (vitamin E), positive or negative charged phospholipids to prevent liposome aggregation and freeze dry agents (English translation of CN ‘649). The composition of CN ‘649 can have a range that encompasses both diameters of liposomes in the first and second liposome ranges via 50 to 5000 nm and 100 to 1500 nm. Thus, having these size ranges would allow for having populations of liposomes in both these ranges. One of ordinary skill in the art before the time of filing would have been capable of adjusting the formulation to having 60% of phosphatidylserine as CN ‘649 allows for other possible membrane components, and thus, one can add other components like lecithin and change the amounts of these membrane components as desired (MPEP 2144.05). Note that 66% by weight of phosphatidylserine is a near value to 60% by weight. In regard to applicant claim 2, the amounts of particles would differ based on size distributions that fit within the ranges of CN ‘649 where CN ‘649 does provide that the average particle sizes are distributed through the range. Claims 3, 5, 6, 8 and 17-20 in addition to Claims 1, 2, 4, 7, 10, 11, and 16 are rejected under 35 U.S.C. 103 as being unpatentable over CN101502649A and Comamala WO2015107140A1. CN ‘649 teaches the claims as discussed above. CN ‘649 does not teach the limitations of claims 2, 3, 5, 6, 8, 17 and 20. Comamala teaches liposomes encapsulating autoantigens (another type of antigen). The liposome membranes have phosphatidylserine in an amount of 10-40% by weight with respect to the total membrane composition (abstract). Comamala teaches pharmaceutical or veterinary compositions with the liposomes for use in treating autoimmune diseases (abstract). The figure 3-5 legends provide for insulin peptides. Comamala teaches peptides with 5 to 100 amino acids or 8 to 50 amino acids (page 15). Comamala teaches “Other autoantigenic proteins or peptides that are associated to autoimmune diseases and may be encapsulated in the liposomes Of the invention are, for example, peptides from myelin for multiple sclerosis, such as peptides derived from myelin-oligodendrocyte glycoprotein (MOG), peptides from acetylcholine receptor for myasthenia gravis, transglutaminase for celiac disease, thyroglobulin for autoimmune thyroiditis” (page 15). Comamala teaches liposomes with PS:PC:cholesterol ratio of 0.9:0.0.9:1 to 1.1:1.1:1.4 (page 16, also see page 18). Comamala teaches different administrations of the formulation (pages 19-20). Claim 12 of Comamala provides for excipients and carriers. One of ordinary skill in the art before the time of filing would have constituted liposomes by teachings of CN ‘649 and Comamala with adjustments in phosphatidtylserine:phosphatidylcholine:cholesterol ratio as seeing their liposome compositions effective for antigen delivery and utilized such liposomes to treat autoimmune diseases including those caused by insulin (a protein capable of activating autoimmune response) through administration of the antigen containing liposomes as both references provide liposomal compositions for delivery of antigens for treatment of a subject. One of ordinary skill in the art would have seen the liposomal antigen as being modifiable based on the disease to be treated in the subject (e.g. viral, autoimmune or other) based on teachings of the prior art. Claim 9 in addition to Claims 1, 2, 4, 7, 10, 11, and 16 is rejected under 35 U.S.C. 103 as being unpatentable over CN101502649A and Kazemi et al (Archives of Razi Institute, Feb 2022, volume 77, pages 37-44). CN’ 649 teaches the claims as discussed above. CN ‘649 does not teach the antigen being a viral capsid protein. Kazemi teaches nanoliposomes containing isolated VP1 protein of foot and mouth disease virus (abstract). Kazemi teaches the VP1 protein being prepared in a liposome with phospholipids and cholesterol (abstract). Kazemi teaches “In this study, VP1 protein, one of the most important proteins against the FMD virus in immune response, was used as an antigen containing some specific antigenic situations and also located on the FMDV capsid surface” (Discussion). One of ordinary skill in the art before the time of filing would have utilized VP1 antigens in liposome formulations seen as beneficial in CN ‘649 as they are seen as effective against viral disease (foot and mouth disease). Therefore, there was a reasonable expectation of success in substituting another antigen for treating disease in formulations o CN ‘649 and obtaining the treatment of the disease that the antigen is designed for. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARK V STEVENS whose telephone number is (571)270-7080. The examiner can normally be reached M-F 9:00 am to 6:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached on (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARK V STEVENS/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

May 22, 2025
Application Filed
Jul 16, 2025
Response after Non-Final Action
Oct 29, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778890
DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS
2y 5m to grant Granted Nov 03, 2026
Patent 12765573
SOFT CANDY WITHOUT FISHY TASTE OR ODOR AND PREPARATION METHOD THEREOF
2y 11m to grant Granted Oct 20, 2026
Patent 12751917
HYDROGELS AS ORAL DELIVERY DOSAGE FORMS, METHODS OF MAKING AND USING SAME
6y 1m to grant Granted Oct 06, 2026
Patent 12751959
CANNABIDIOL NANODRUG FORMULATIONS AND METHODS FOR USE OF THE SAME
3y 4m to grant Granted Oct 06, 2026
Patent 12751928
PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF SULTIAME
2y 11m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+41.6%)
2y 8m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 879 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month